Novartis AG’s transfer of Phase III BRAF and MEK inhibitor drugs to partner Array BioPharma Inc. will clear the way for its acquisition of GlaxoSmithKline PLC’s oncology portfolio.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?